Stem, Inc. (STEM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

For now, stem cell therapy is most likely to help people who have active inflammation or frequent relapses. Research does not suggest ... That can mean even the typically fluctuating copays ...

Earnings Estimate Revisions for Stem This company is expected to earn -$0.52 per share for the fiscal year ending December 2024, which represents a year-over-year change of 42.2%. Analysts have ...